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Background: Targeted therapy with tyrosine kinase inhibitors has been shown to reduce tumor volumes and
prolong the survival of patients with metastatic renal cell carcinoma. Tyrosine kinase inhibitors, particularly sunitinib,
have recently been used in neoadjuvant and presurgical settings. Axitinib is a promising second-line therapy option
for advanced or metastatic renal cell carcinoma. Herein, we report a patient with advanced renal cell carcinoma
who received presurgical treatment with axitinib.
Case presentation: A 73-year-old man was transported by ambulance to a community hospital with chief
complaints of high fever and a gait disorder. Computed tomography screening revealed a hypervascular
tumor (size, 9 × 8.5 cm) in the lower pole of the left kidney. Upon admission to our hospital, his general condition
was poor and his performance status was judged as 3, based on the Eastern Cooperative Oncology Group
performance status criteria. After biopsy for the renal tumor, he received 5 mg of axitinib twice daily for 3 months.
No serious adverse events were reported during this treatment. The tumor diameter shrank by 56%. Left radical
nephrectomy was performed, and there were no intraoperative or postoperative complications. Pathological
examination indicated a pT3aN0M0, Furman grade 3, clear cell renal cell carcinoma with necrosis, hyaline degeneration,
and hemosiderosis. The patient was asymptomatic and disease-free at 1 year post-diagnosis.
Conclusion: This case study demonstrate that presurgical therapy with axitinib is feasible and might have several
potential advantages for patients with advanced renal cell carcinoma.
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Targeted therapy with tyrosine kinase inhibitors (TKIs)
has been shown to reduce primary or metastatic tumor
volumes and prolong the survival of patients with meta-
static renal cell carcinoma (RCC) [1,2]. TKIs, particularly
sunitinib, have recently been used in neoadjuvant or pre-
surgical settings to facilitate surgery by reducing tumor
sizes [2,3]. The potential benefits of neoadjuvant or pre-
surgical therapy include local tumor downstaging, elim-
ination of micrometastatic disease, and diminution of
postoperative metastatic progression.
However, targeted therapy with TKIs has elicited some
concerns regarding complications. The commonly re-
corded grade 3/4 clinical toxicities associated with sunitinib* Correspondence: coyama@cc.hirosaki-u.ac.jp
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reproduction in any medium, provided the orwere gastrointestinal disorders including diarrhea or
anorexia, and hematotoxicity including neutropenia or
thrombocytopenia [1]. Targeted therapy regimens should
be less toxic to prevent any treatment-related delays be-
tween neoadjuvant therapy and surgery and to achieve
better oncologic outcomes in a neoadjuvant setting.
Axitinib is a promising second-line therapy option for
advanced or metastatic RCC [4]. In Japanese patients
with metastatic RCC, adverse events with sunitinib was
severer than the Caucasian population [5]. Additionally,
this agent has shown anti-tumor activity and has an
acceptable safety profile [6]. We designed a phase II
single-arm trial to evaluate safety and effectiveness of
presurgical treatment of advanced RCC with axitinib.
This patient was enrolled this trial. Herein, we report a
patient with advanced RCC who received presurgical
treatment with axitinib. The patient was informed about
the treatment protocol and provided written informed. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Abdominal enhanced computed tomography (CT)
before axitinib treatment. (coronal section) Abdominal CT shows a
hypervascular tumor (size, 9 × 8.5 cm) in the lower pole of the
left kidney.
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uments were reviewed and approved by the Hirosaki
University Institutional Review Board.
Case presentation
A 73-year-old man was transported by ambulance to
a community hospital with chief complaints of high
fever and a gait disorder. Laboratory evaluations re-
vealed the following findings: hemoglobin, 7.0 g/dL
(normal range, 13.5-17.5 g/dL); creatine phosphoki-
nase, 572 IU/L (normal range, 60-270 IU/L); free blood
sugar, 226 mg/dL (normal range, 70-109 mg/dL); and C-
reactive protein, 14.0 mg/dL (normal range, <0.3 mg/dL).
Computed tomography (CT) screening revealed a hyper-
vascular tumor (size, 9 × 8.5 cm) in the lower pole of
the left kidney (Figure 1). The tumor was clinically
diagnosed as a left RCC with a classification of cT2aN0M0,Figure 2 Abdominal enhanced computed tomography (CT) after axiti
shows a hypervascular tumor (size, 4.5 × 2.5 cm) in the lower pole of the le
axitinib treatment.according to the tumor-node-metastasis system [7]. The
patient was transferred to our hospital for surgical
treatment.
Upon admission to our hospital, the patient’s general
condition was poor and his performance status (PS) was
judged as 3, based on the Eastern Cooperative Oncology
Group performance status criteria. Laboratory evaluations
revealed the following findings: hemoglobin, 6.8 g/dL; ad-
justed calcium, 12.7 mg/dL (normal range, 8.7-10.3 g/dL);
and alkaline phosphatase, 1670 U/L (normal range: 115-
359 U/L). The patient underwent renal biopsy and was
diagnosed with clear cell carcinoma of the left kidney.
He received 5 mg of axitinib twice daily for 3 months,
because we thought that immediate radical surgery was
not safe because of his poor performance status and la-
boratory data paraneoplastic syndrome. Fortunately, no
serious adverse events were reported during this treat-
ment. The patient convalesced during the administra-
tion of axitinib, and all laboratory data were restored
to within normal limits after axitinib treatment. An ab-
dominal CT after the axitinib therapy showed that the
tumor diameter shrank by 56% (Figure 2A, B). At that
time, we were convinced that his renal tumor could
be removed safely. Left radical nephrectomy was per-
formed. The operation time was 95 min, and the es-
timated blood loss was 50 mL. No intraoperative or
postoperative complications including wound healing
delay or hemorrhage resulted from surgery. Macro-
scopic examination revealed a solid, yellowish-white
tumor measuring 4 × 2.5 cm in size, with necrosis in
the lower pole of the resected kidney (Figure 3). Patho-
logical examination indicated pT3aN0M0, Furman grade 3,
clear cell RCC with necrosis, hyaline degeneration,
and hemosiderosis (Figure 4). Fifty percent of tumor
tissue was necrosis, and it was central necrosis. The
patient was asymptomatic and disease-free at 1 year
post-diagnosis.nib treatment. (A, axial section; B, coronal section). Abdominal CT
ft kidney. The tumor diameter shrank by 56%, compared to that before
Figure 3 Macroscopic findings. Macroscopic examination reveals a
solid tumor measuring 4 × 2.5 cm in size in the lower pole of the
resected kidney (arrow).
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To the best of our knowledge, this is the first reported
case of presurgical axitinib therapy in a patient with
RCC.
Targeted molecular therapies such as sunitinib have
changed the management of advanced or metastatic
RCC. TKIs have significantly improved progression-free
survival, and sunitinib, in particular, achieved a median
overall survival of >2 years in advanced RCC patients
[8,9]. Therefore, neoadjuvant or presurgical treatments
have been suggested as treatment options for patients
with advanced or unresectable RCC. Several studiesFigure 4 Hematoxylin-eosin stained section. The pathological
findings indicate clear cell renal cell carcinoma with necrosis, hyaline
degeneration, and hemosiderosis (magnification: ×200).suggested that targeted therapies in the neoadjuvant
setting were safe, well tolerated, and did not increase
surgical morbidity or perioperative complications in
selected patients [2,3,10]. However, these findings have
been limited to small, uncontrolled, single-institution
studies.
Potential disadvantages of presurgical or neoadjuvant
targeted therapy include the lack of optimal surgical
timing after systemic therapy and the risk of increased
surgical morbidity [11]. Recent reports have cited com-
plications such as poor wound healing and hemorrhage
[12]. Chapin reported that presurgical targeted therapy
remained a significant predictor of wound complica-
tions in a multivariate analysis (odds ratio, 4.14; P = 0.03)
[13]. In a prospective study, the incidence of delayed super-
ficial wound healing was higher in patients who re-
ceived preoperative bevacizumab than in a historic
matched cohort of 101 patients who underwent up-
front surgery [14].
Axitinib is a potent and selective second-generation
inhibitor of vascular endothelial growth factor receptor-
1, 2, and 3 [15]. Axitinib has shown anti-tumor activity
as a single agent with an acceptable safety profile in sev-
eral solid tumors including previously treated metastatic
RCC [4,6]. Adverse events observed in Japanese patients
as well as in the overall axitinib-treated population, in-
cluded diarrhea, hypertension, and fatigue [16]. Although
axitinib was less effective for patients with poor PS [4], axi-
tinib was generally well tolerated and had an acceptable
safety profile in Japanese patients with metastatic RCC.
Therefore, axitinib was administered for advanced RCC in
this case.
In conclusion, this case study indicates that presurgical
targeted therapy with axitinib might have several poten-
tial advantages for patients with advanced RCC. How-
ever, the indications and clinical benefits of neoadjuvant
or presurgical axitinib therapy remain to be determined.
It will thus be necessary to investigate many cases in a
large clinical study.
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